{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:14:34Z","timestamp":1778649274314,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The main cause of death for chronic kidney disease (CKD) is cardiac arrest caused by life-threatening arrhythmias, such as ventricular arrhythmia (VA) and atrioventricular block (AVB). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been proven to have a preventive effect on atrial arrhythmia. This meta-analysis aimed to evaluate whether SGLT2i could prevent life-threatening arrhythmias in CKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane Library, and Clinical Trials.gov until August 2025. Randomized controlled trials (RCTs) that compared the effect of SGLT2i and placebo on cardiac arrest, VA, and AVB in CKD patients were included. VA included ventricular tachycardia (VT), ventricular flutter (VFL), and ventricular fibrillation (VF). AVB only included second-degree and third-degree AVB. Risk ratio (RR) with 95% confidence interval (CI) was calculated using a random-effects model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      8 RCTs were included. Among them, 7 RCTs reported cardiac arrest, 5 reported VA, and 5 reported AVB. SGLT2i could reduce the risk of cardiac arrest in CKD patients (0.12% vs. 0.23%; RR 0.53, 95% CI 0.29\u20130.95,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03), while didn't reduce the risk of VA (0.09% vs. 0.12%; RR 0.72, 95% CI 0.34\u20131.55,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.40) and AVB (0.15% vs. 0.19%; RR 0.77, 95% CI 0.42\u20131.40,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.38). Subgroup analyses revealed that SGLT2i did not prevent the incidents of VF\/VFL (RR 0.42, 95% CI 0.13\u20131.34,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.14), VT (RR 1.20, 95% CI 0.42\u20133.43,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.74), second-degree (RR 2.03, 95% CI 0.65\u20136.33,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.22) and third-degree (RR 0.51, 95% CI 0.24\u20131.08,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.08) AVB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SGLT2i could reduce the risk of cardiac arrest in CKD patients, but had no effect on specific types of life-threatening arrhythmias, such as VT, VF\/VFL, second-degree and third-degree AVB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261388417<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1781810","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:44:43Z","timestamp":1778647483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The preventive effect of sodium-glucose co-transporter-2 inhibitors on life-threatening arrhythmias in patients with chronic kidney disease: a meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Medicine Translational Research on Cardiovascular Disease, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjian","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuodong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]},{"name":"Hebei Key Laboratory of Precision Medicine Translational Research on Cardiovascular Disease, Hebei General Hospital","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.3390\/ijms25052658","article-title":"Novel perspectives in chronic kidney disease-specific cardiovascular disease","volume":"25","author":"Xu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"C525","DOI":"10.1152\/ajpcell.00143.2024","article-title":"Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions","volume":"327","author":"Girardi","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12933-024-02312-0","article-title":"The potential anti-arrhythmic effect of SGLT2 inhibitors","volume":"23","author":"Duan","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1585491","DOI":"10.3389\/fphar.2025.1585491","article-title":"The preventive effect of sodium-glucose co-transporter-2 inhibitors on atrial fibrillation and atrial flutter in patients with chronic kidney disease: a meta-analysis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1558367","DOI":"10.3389\/fphar.2025.1558367","article-title":"Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.31083\/j.rcm2409258","article-title":"Association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) with cardiac arrhythmias: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"24","author":"Wang","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","article-title":"Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Barnett","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/dom.12348","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"16","author":"Yale","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment","volume":"23","author":"Cherney","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1053\/j.ajkd.2011.02.376","article-title":"Sudden cardiac death in hemodialysis patients: an in-depth review","volume":"57","author":"Green","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/europace\/euac032","article-title":"Nationwide study of mortality and sudden cardiac death in young persons diagnosed with chronic kidney disease","volume":"24","author":"Svane","year":"2022","journal-title":"Europace"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.3390\/medicina59101760","article-title":"Associations between oral glucose-lowering agents and increased risk for life-threatening arrhythmias in patients with type 2 diabetes Mellitus. A literature review","volume":"59","author":"Tudoran","year":"2023","journal-title":"Med Kaunas Lith"},{"key":"B21","doi-asserted-by":"publisher","first-page":"501345","DOI":"10.1016\/j.nefroe.2025.501345","article-title":"Safety and efficacy of sodium-glucose co-transporter-2 inhibitors and aldosterone inhibitors combinations in chronic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Hageen","year":"2011","journal-title":"Nefrologia (Engl Ed)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.jacadv.2025.101615","article-title":"Sodium-Glucose cotransporter-2 inhibitors and arrhythmias: a meta-analysis of 38 randomized controlled trials","volume":"4","author":"Jaiswal","year":"2025","journal-title":"JACC Adv"},{"key":"B23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00392-024-02386-6","article-title":"Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"113","author":"Xu","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.3390\/jcm14155306","article-title":"SGLT2 Inhibitors and the risk of arrhythmias in heart failure: a network meta-analysis","volume":"14","author":"Suresh","year":"2025","journal-title":"J Clin Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13643-025-02766-7","article-title":"Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials","volume":"14","author":"Lin","year":"2025","journal-title":"Syst Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1681\/asn.20233411s11044c","article-title":"Association between longitudinal eGFR and sudden cardiac death among CKD patients","volume":"34","author":"Delannoy","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1093\/eurheartj\/ehaf167","article-title":"Cardiovascular disease in chronic kidney disease","volume":"46","author":"Marx-Sch\u00fctt","year":"2025","journal-title":"Eur Heart J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108973","DOI":"10.1016\/j.pharmthera.2025.108973","article-title":"SGLT2 Inhibitors: do they have antiarrhythmic properties?","volume":"279","author":"Caballero","year":"2026","journal-title":"Pharmacol Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacbts.2020.01.011","article-title":"Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?","volume":"5","author":"Verma","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/s41440-025-02216-w","article-title":"Interaction between SGLT2 and the sympathetic nervous system in normal and various cardiovascular metabolic disease states","volume":"48","author":"Katsurada","year":"2025","journal-title":"Hypertens Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/CIRCRESAHA.122.319989","article-title":"Cardiorenal syndrome: the role of neural connections between the heart and the kidneys","volume":"130","author":"Patel","year":"2022","journal-title":"Circ Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1161\/CIRCEP.108.817320","article-title":"Cardiac metabolism and arrhythmias","volume":"2","author":"Barth","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12916-021-02185-0","article-title":"Ketone bodies: from enemy to friend and guardian angel","volume":"19","author":"Kolb","year":"2021","journal-title":"BMC Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1781810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:44:55Z","timestamp":1778647495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1781810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":33,"alternative-id":["10.3389\/fcvm.2026.1781810"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1781810","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1781810"}}